“In 2007, we will fund multiple trials of our telomerase inhibitor drug, GRN163L, and we anticipate initiating a clinical trial for our cancer vaccine,” said David Greenwood, Geron’s executive vice president and chief financial officer. “We are also on a path to a regulatory filing and clinical trial for TAT0002, our telomerase activator drug, for patients with HIV/AIDS. Finally, we expect to file an IND to treat spinal cord injury using therapeutic cells derived from human embryonic stem cells. We want to maintain a strong balance sheet as we progress to and through these and potentially other trials.”